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Abstract
Background: Glutathione (GSH) plays an important role in neuronal oxidant defence. Depletion of cellular GSH is
observed in neurodegenerative diseases and thereby contributes to the associated oxidative stress and Ca
2+
dysregulation. Whether depletion of cellular GSH, associated with neuronal senescence, directly influences Ca
2+
permeation pathways is not known. Transient receptor potential melastatin type 2 (TRPM2) is a Ca
2+ permeable
non-selective cation channel expressed in several cell types including hippocampal pyramidal neurons. Moreover,
activation of TRPM2 during oxidative stress has been linked to cell death. Importantly, GSH has been reported to
inhibit TRPM2 channels, suggesting they may directly contribute to Ca
2+ dysregulation associated with neuronal
senescence. Herein, we explore the relation between cellular GSH and TRPM2 channel activity in long-term cultures
of hippocampal neurons.
Results: In whole-cell voltage-clamp recordings, we observe that TRPM2 current density increases in cultured
pyramidal neurons over time in vitro. The observed increase in current density was prevented by treatment with
NAC, a precursor to GSH synthesis. Conversely, treatment of cultures maintained for 2 weeks in vitro with L-BSO,
which depletes GSH by inhibiting its synthesis, augments TRPM2 currents. Additionally, we demonstrate that GSH
inhibits TRPM2 currents through a thiol-independent mechanism, and produces a 3.5-fold shift in the dose-
response curve generated by ADPR, the intracellular agonist for TRPM2.
Conclusion: These results indicate that GSH plays a physiologically relevant role in the regulation of TRPM2
currents in hippocampal pyramidal neurons. This interaction may play an important role in aging and neurological
diseases associated with depletion of GSH.
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Introduction
Aging is a major risk factor for developing several neu-
rodegenerative diseases. Although the precise reasons
are poorly understood, a growing body of evidence sug-
gests that age-related cognitive decline is associated with
stereotypic changes in cellular homeostasis which ulti-
mately lead to impaired neuronal function [1]. A leading
hypothesis suggests that increased oxidative stress asso-
ciated with aging predisposes neurons to dysregulated
intracellular Ca
2+ homeostasis in response to disease
causing factors [2]. Accordingly, understanding the rela-
tion between oxidative stress and altered Ca
2+ homeos-
tasis may provide valuable insight into mechanisms
underlying neurodegenerative disease.
Glutathione (GSH), the most abundant intracellular
reducing agent [3], plays an important role in limiting
cellular damage by reactive oxygen and nitrogen species
generated as a by-product of aerobic metabolism. Cellu-
lar levels of GSH are known to decrease with age [4-9]
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viewed as a risk factor contributing to the increased sus-
ceptibility to neurodegenerative disease associated with
aging. For example, a strong relationship has been
demonstrated between reduced levels of GSH and Par-
kinson’s disease [10-16]. Furthermore, a reduction in
glutathione has also been associated with cerebral ische-
mia [13-16]. Importantly, depletion of GSH itself leads
to increased oxidative stress, altered Ca
2+ homeostasis
and increased neuronal cell death [17-20]. It is unknown
whether depletion of GSH promotes Ca
2+ dysregulation
directly (e.g. by altering Ca
2+ permeation pathways) or
through the induction of oxidative stress.
TRPM2 is a highly unique calcium permeable non-
selective cation channel that is responsive to reactive
oxygen and nitrogen species (ROS/RNS). Channel acti-
vation by ROS/RNS is proposed to occur following the
generation of adenosine diphosphate ribose (ADPR),
which serves as an intracellular agonist [21]. Notably,
gating is also greatly facilitated by elevated concentra-
tions of intracellular Ca
2+ [22,23]. TRPM2 expression is
highest within the brain [24] and recent work in our lab
demonstrated that TRPM2 is expressed and functional
in pyramidal neurons of the hippocampus [23], a subset
of neurons that are particularly susceptible to oxidative
stress-induced damage in stroke and neurodegenerative
disease [25,26]. This current was absent in primary hip-
pocampal neurons cultured from TRPM2 knockout
(KO) animals [27]. Importantly, TRPM2 has been
shown to contribute to cell death in response to oxida-
tive stress, TNFa,a m y l o i d - b peptide, and ischemia
[28-30]. These findings raise the possibility that TRPM2
may play an important role in neurological diseases
associated with aging, excitotoxicity and oxidative stress.
Recent evidence suggests that TRPM2 channels may
be directly regulated by GSH. Indeed, GSH has been
shown to inhibit TRPM2 currents in astrocytes, micro-
glia, and dorsal root ganglion sensory neurons [20,31].
Importantly, these papers did not investigate the effects
of glutathione on TRPM2 channels in neurons suscepti-
ble to degeneration. Furthermore, the mechanism
responsible for the observed inhibition was not explored.
We now extend previous findings demonstrating
GSH-mediated inhibition of TRPM2 currents by demon-
strating that intrinsic, age-dependent, variations in the
intracellular concentration of GSH is a key determinant
in dictating the level of TRPM2 activation in neurons.
Moreover, we demonstrate that the inhibition of
TRPM2 function by GSH operates independently of its
capacity as a reducing agent. These findings suggest that
altered intracellular Ca
2+ dynamics associated with GSH
depletion, induced experimentally or with aging, may
develop as a result of altered TRPM2 regulation.
Results
TRPM2 currents increase with time in vitro
Primary neuronal cultures are often used to examine
neuronal development; however, beyond 21 days in
vitro, early neuronal markers such as nestin drastically
diminishes in expression, and mature neuronal markers
such as MAP-2 are expressed, indicative of a mature
neuronal population [32]. Furthermore, cultures main-
tained beyond 3 weeks in vitro recapitulate many of the
characteristic cellular changes that have been associated
with aging and neurodegeneration [32-35]. These
include increased oxidative stress, lipid peroxidation,
protein tyrosine nitration, mitochondrial injury, ER
stress, DNA damage, Ca
2+ dysregulation, calpain clea-
vage, endogenous Ab accumulation, and susceptibility to
neuronal cell death. Importantly, in primary neuronal
cultures the concentration of GSH has also been shown
to decrease with time in vitro [36,37]. Accordingly,
long-term neuronal cultures serve as a valuable model
system for the study of cellular changes associated with
neuronal aging and senescence. With this in mind, we
first sought to determine whether in vitro neuronal
senescence correlates with altered TRPM2 function.
To rigorously examine TRPM2 function over time in cul-
ture, whole-cell voltage-clamp recordings were made from
primary hippocampal neuronal cultures maintained in vitro
for up to 28 days. Using a previously established protocol
[23], TRPM2 currents were evoked by intracellular admin-
istration of ADPR paired with repeated N-methyl-D-aspar-
tate (NMDA) receptor (NMDAR) stimulation. Importantly,
the currents generated using this protocol can be entirely
attributed to TRPM2 channels as they are abolished by
known blockers of TRPM2 [23]. To ensure that the full
complement of TRPM2 channels expressed at various time
points are being activated in our recordings, a saturating
concentration of ADPR (1 mM) was included in the patch
pipette. Furthermore, as the neuronal cell surface area
increases over time due to the continued extension of neu-
ronal processes, TRPM2 currents were normalized to
membrane capacitance, measurement of which correlates
with cell surface area (p < 0.05, data not shown). As illu-
strated by the representative traces shown in Figure 1A and
1B, repeated applications of NMDA to pyramidal neurons
loaded with ADPR caused the progressive development of
large inward currents, the amplitudes of which stabilized
within approximately 5-15 min. The amplitude of TRPM2
currents was then determined after removal of extracellular
Ca
2+, a protocol known to abolish TRPM2-mediated cur-
rents [23,27]. Recordings were made from neurons at 14,
20, and 26 days in vitro (DIV, n = 5/group). Results demon-
strate that there is an increase in TRPM2 current density
between 14 and 26 DIV in cultured hippocampal pyramidal
neurons (Figure 1C, p < 0.05). Since activation of the
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analyzed whether the NMDAR current density is increased
over time in vitro. No change was observed over this same
time period (p = 0.76, Figure 1D). Furthermore, we assessed
whether a change in NMDAR kinetics may explain the
enhanced TRPM2 response by calculating the integral
under the NMDAR application and normalized this mea-
surement to capacitance (Q/pF). Similarly, no change was
observed from 2 - 4 weeks in vitro (data not shown,
p =0 . 3 9 ) .
TRPM2 mRNA does not change with time in vitro
Increased TRPM2 current density with time in vitro
could be attributed to an increase in the function of
TRPM2, potentially via a decrease in glutathione, or
alternatively an increase in TRPM2 expression. Using
real-time quantitative PCR (RT-QPCR), we tested
whether TRPM2 mRNA increases with time in vitro in
primary hippocampal cell culture. Total RNA from cells
at 15 (n = 9), 22 (n = 8), and 29 (n = 9) DIV were run in
duplicate and TRPM2 levels were quantified. Results
were normalized to neuron-specific enolase (Eno2) by
calculating delta cycle threshold (ΔCT) values for each
sample (NSE CT - TRPM2 CT) in order to control for
any variability in neuronal content over time. Analysis by
one-way ANOVA revealed no change in the TRPM2
cycle threshold (p = 0.89, Figure 2A), Eno2 (p =0 . 9 ,F i g -
ure 2B) or normalized TRPM2 mRNA levels over time in
vitro (p = 0.51, Figure 2C). These findings demonstrate
that changes in mRNA expression levels are not respon-
sible for the increase in TRPM2 current density observed
over time in vitro.
Modulation of glutathione alters TRPM2 currents in
hippocampal pyramidal neurons
If decreased cellular GSH content is responsible for ele-
vated TRPM2 function over time in vitro then enhancing
intracellular GSH levels should diminish TRPM2 current
amplitude in older cultured neurons (~28 DIV). Conver-
sely, reducing intracellular GSH levels should facilitate
TRPM2 channel function in younger neuronal cultures
(~14 DIV).
We first examined the consequence of elevating the
intracellular concentration of GSH in neurons at
Figure 1 TRPM2 currents are enhanced in hippocampal pyramidal neurons with time in vitro. With 1 mM ADPR included in the patch
pipette, TRPM2 currents developed slowly following repeated (1/60 sec) applications NMDA (100 μM, for 5 sec). TRPM2 currents were quantified
by removing extracellular calcium and amplitude was normalized to cell capacitance. NMDA applications are indicated with solid lines. Calcium-
free application is depicted as a dashed line (A) Representative trace of TRPM2 currents recorded at 14 DIV (B) Representative trace of TRPM2
currents recorded at 25 DIV. (C) Current density at 14, 20, and 26 DIV (n = 5 per group) were compared by one-way ANOVA followed by post-
hoc Tukey’s test. A significant increase in TRPM2 current density between 14 and 26 DIV was observed (p < 0.05). (D) NMDAR current density is
not significantly increased over time in vitro (p = 0.76).
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patch pipette. When compared with controls, GSH (10
mM) significantly inhibited TRPM2 currents activated
i nt h ep r e s e n c eo fA D P Rb yt h eN M D A Rs t i m u l a t i o n
protocol (Figure 3A, p = 0.04). In millimolar concentra-
tions, extracellular GSH has been shown to enhance
NMDAR function [38,39]. No difference in NMDAR
amplitude was observed with intracellular delivery of
GSH (p = 0.82, data not shown). Representative traces
are shown in Figure 3B (control) and Figure 3C (10 mM
GSH). To confirm the effects of GSH on TRPM2 cur-
rents, we also examined the effects of GSH delivered
through the patch pipette on TRPM2 currents generated
by a voltage ramp protocol. Using this alternative proto-
col, GSH similarly inhibited TRPM2 currents (Figure
3D, p = 0.01). Examples of representative traces for con-
trol and GSH voltage ramp recordings are shown in Fig-
ure 3E and 3F, respectively.
We next sought evidence that augmenting endogenous
GSH content can similarly decrease TRPM2 function.
We chronically treated neurons from 1-4 weeks in vitro
with N-acetyl-cysteine (NAC), a precursor to GSH that
has been shown to increase levels of endogenous GSH
[14,40-42] and examined whether TRPM2 currents in
cultures at 4 weeks in vitro were reduced. Treatment
with 50 μM NAC beginning at 1 week in vitro signifi-
cantly attenuated TRPM2 currents in cultures at 28 DIV
(p = 0.04, Figure 4A-C). Previous studies have shown
that NAC is able to act as a reactive oxygen scavenger
independent of its ability to upregulate GSH [43]. To
confirm that the observed effect can be attributed to
GSH and not to NAC itself, NAC (50 μM) was included
in the patch pipette and TRPM2 currents were elicited
with the NMDA activation protocol with 1 mM ADPR
in the patch pipette. Compared to controls (1076 ±
204.9, n = 3), acute NAC (910.5 ± 142.8 n = 4) did not
alter TRPM2 currents (p = 0.52, data not shown). These
results confirm previous findings that GSH can inhibit
TRPM2 currents, and are consistent with the notion
that reduced GSH, at least in part, may underlie the
increase in TRPM2 currents that we observed in hippo-
campal pyramidal neurons over time in vitro. These
findings also imply that GSH constitutively suppresses
TRPM2 function in younger cultured neurons.
Accordingly, we next examined whether depleting GSH
could augment TRPM2 function in young cultures main-
tained for 2 weeks in vitro. L-buthionine-(S, R)-sulfoxi-
mine (L-BSO) inhibits the enzyme g-glutamylcysteine
synthetase, the rate limitings t e pi nG S Hs y n t h e s i s[ 4 4 ]
and is effective in depleting GSH [14,18,36,42,45]. Consis-
tent with our hypothesis, TRPM2 currents were signifi-
cantly potentiated, when compared with controls (p =
0.01), in 2 week old cultured neurons depleted of GSH by
treatment with 250 μM L-BSO for 48 hours (Figure 4D-F).
Mechanism of TRPM2 inhibition by GSH
HEK 293 cells stably expressing TRPM2 under control of
an inducible promoter (TRPM2-HEK293) were used to
characterize the mechanism of glutathione-mediated
TRPM2 inhibition. To further validate our findings in hip-
pocampal pyramidal neurons, and previous findings in
glial and dorsal root ganglion cells [20,31], TRPM2 cur-
rents from TRPM2-HEK293 cells were recorded in the
whole-cell patch clamp configuration with 0.1 mM ADPR
in the patch pipette. Of note, HEK293 cells do not express
NMDARs nor voltage-gated Ca
2+ channels. However,
intracellular application of ADPR alone is sufficient to
activate TRPM2 channels in this model system, presum-
ably due to the much higher induced channel expression.
Currents generated under control conditions were com-
pared to those generated when 10 mM GSH was included
in the patch pipette, and removal of extracellular Ca
2+ was
used to abolish the TRPM2 current. In the presence of
exogenously delivered intracellular GSH, a substantial
attenuation of the TRPM2 current was observed (Figure 5,
p<0 . 0 0 1 ) .
GSH may regulate channel function through a number
of distinct mechanisms including redox mechanisms as
Figure 2 TRPM2 mRNA levels do not change in hippocampal
primary cultures with time in vitro.( A) TRPM2 mRNA was
measured at 14, 21, and 29 DIV (n = 8 per group) by quantitative
real-time PCR (qPCR). No significant change in cycle threshold
values is observed (p = 0.89) (B) QPCR analysis of neuron specific
enolase (ENO2) mRNA values used to control for neuronal content
over time. No significant difference was observed (p = 0.9). (C)
Normalized TRPM2 values for each sample (ENO2-TRPM2) were
quantified. No difference in the normalized levels of TRPM2 mRNA
is seen over time in culture (p = 0.51).
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Page 4 of 11Figure 3 Glutathione inhibits TRPM2 currents in hippocampal pyramidal neurons.( A)1 0m MG S Hi nt h ep a t c hp i p e t t es i g n i f i c a n t l y
inhibits TRPM2 currents generated by 1 mM ADPR with an NMDAR stimulation protocol (p = 0.04). (B, C) Representative traces of control and
GSH inhibition with the NMDAR stimulation protocol. (D)10 mM GSH in the patch pipette significantly inhibits TRPM2 currents generated by 1
mM ADPR with a voltage ramp protocol (p = 0.01). (E,F) Representative traces of control and GSH inhibition with the voltage ramp protocol.
Belrose et al. Molecular Brain 2012, 5:11
http://www.molecularbrain.com/content/5/1/11
Page 5 of 11well as post-translational modification involving the for-
mation mixed protein disulfides (i.e. glutathionylation).
For example, through its reducing potential GSH has
been shown to regulate the function of other receptors
and channels, including NMDARs [38,46]. To examine
the possibility that TRPM2 is regulated through changes
in its redox state, we examined whether the inhibitory
effect of GSH could be mimicked by another reducing
agent, dithiothreitol (DTT). DTT was included in the
patch pipette and currents were recorded from TRPM2-
H E K 2 9 3c e l l s .A t1 0m MD T T ,n oc h a n g ei nT R P M 2
amplitude was observed when compared to controls (p >
0.05; Figure 5), suggesting that the reducing ability of
GSH is not responsible for the change in TRPM2
currents.
GSH has also been shown to inhibit currents through
direct binding to channels, either at thiol residues,
known as glutathionylation, or at other non-thiol con-
taining binding sites [47-49]. Ophthalmic acid (g-gluta-
myl-2-amino-n-butanoylglycine) is an analogue of GSH
which contains L-2-aminobutyrate in place of the
cysteine residue [50]. This analogue lacks both the ability
to form disulphide bonds and the reducing potential of
GSH. Interestingly, when ophthalmic acid (10 mM) was
included in the patch pipette, TRPM2 currents were sig-
nificantly inhibited in TRPM2-HEK293 cells (p < 0.001;
Figure 4 (A) Treatment from 1-4 weeks in vitro with 50 μM NAC significantly inhibited TRPM2 currents generated by 0.3 mM ADPR
and an NMDAR stimulation protocol in cultures at 28 DIV (p = 0.04).( B, C) Representative control and NAC traces. (D) A 48 hour treatment
with 250 μM L-BSO significantly enhances TRPM2 currents generated with 1 mM ADPR with an NMDAR stimulation protocol in hippocampal
pyramidal neurons at 2 weeks in vitro. (E, F) Representative control and L-BSO traces.
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independent manner to inhibit TRPM2 currents.
Potential mechanisms of TRPM2 inhibition by GSH
were further studied by constructing a concentration-
response relationship for ADPR with or without 10 mM
GSH included in the patch pipette. TRPM2 currents
were evoked with varying intracellular concentrations
(0.03 - 3 mM) of ADPR. Each point on the curve repre-
sents the mean +/- SE of 6 - 11 recordings (Figure 6). A
two-way ANOVA followed by Bonferroni post-hoc test
revealed an overall significant effect, with a highly signifi-
cant inhibition by GSH for TRPM2 currents evoked with
ADPR concentrations of 0.1, 0.3, and 1 mM (p <0 . 0 0 1 ) .
No difference between groups was observed at the high-
est (3 mM) and lowest (0.03 mM) ADPR concentrations
(p > 0.05). In control conditions, the EC50 of ADPR was
77 μM, consistent with a previous report [51]. In con-
trast, the EC50 of ADPR with 10 mM GSH was 269 μM,
representing a ~3.5 fold change in sensitivity when GSH
is included in the patch pipette. Furthermore, the dose-
response curves fit using a sigmoidal dose-response (vari-
able slope), results in a Hill slope of 2.2 in control, and
0.9 in the GSH data set. The rightward shift in the dose-
response relationship and decrease in the Hill coefficient
confirm that GSH inhibits TRPM2 channels. The results
with DTT and ophthalmic acid confirm that the effects
of GSH are thiol-independent. However, whether GSH
functions as a channel blocker, competes for the ADPR
binding site, or interferes with TRPM2 currents by bind-
ing to ADPR requires further investigation.
Discussion
In this study we demonstrate that TRPM2 function
increases with time in vitro in cultured hippocampal pyr-
amidal neurons. Moreover, we show that by altering the
intracellular concentration of GSH TRPM2 current
amplitude can be modulated in this system. Specifically,
this was shown in experiments where GSH was supplied
exogenously through the patch pipette, or alternatively,
where we modulated endogenous GSH metabolism. We
also demonstrate that ophthalmic acid, but not DTT, is
able to recapitulate GSH mediated inhibition of TRPM2
currents, suggesting that GSH inhibits TRPM2 channels
independently of its electron-donating capacity. Lastly, a
3.5-fold shift in the dose-response curve and decrease in
Figure 5 GSH inhibits TRPM2 in a thiol-independent
mechanism. TRPM2 currents were elicited in HEK293-TRPM2 cells
using a 2 mM calcium extracellular solution and 0.1 mM ADPR.
TRPM2 currents were then inhibited and quantified following
removal of extracellular calcium (A) Representative TRPM2 responses
obtained in control (n = 12), GSH (n = 10), DTT (n = 6) and
ophthalmic acid (n = 6) groups (B) TRPM2 currents are significantly
inhibited with 10 mM GSH or 10 mM ophthalmic acid, but are not
altered when 10 mM DTT is included in the patch pipette (One-way
ANOVA followed by post-hoc Tukey’s test, * p < 0.05).
Figure 6 GSH shifts the ADPR dose-response curve of TRPM2
channels by 3.5 fold. TRPM2 currents were generated in with or
without 10 mM GSH included in the patch pipette. Intracellular
concentrations of ADPR used to evoke the current ranged from 0.03
- 3 mM. Each point on the curve represents the mean +/- SE of 6 -
11 recordings. Significant inhibition by GSH was observed for
TRPM2 currents evoked by ADPR concentrations of 0.1, 0.3, and 1
mM (p < 0.001), with no difference between groups at the highest
(3 mM) and lowest (0.03 mM) ADPR concentration points (p > 0.05).
The EC50 value for ADPR was increased from 77 μM (control) to 269
μM (10 mM GSH) in the presence of 10 mM GSH, representing a
~3.5 fold change in sensitivity to ADPR. Dose-response curves were
fit using a sigmoidal dose-response (variable slope), with a Hill slope
of 2.2 in control, and 0.9 in the GSH data set.
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suggest that GSH either disrupts the co-operative inter-
action between ADPR and TRPM2 or functions as a
channel blocker. Further research is required to deter-
mine the precise nature of this interaction. The mechan-
ism through which GSH inhibits TRPM2 and its
relevance to the regulation of the channel in neurons is
crucial to understand pathways leading to neurotoxicity.
TRPM2 is a Ca
2+ permeable non-selective ion channel
implicated in oxidative stress-induced cell death [28-30].
Several factors have been reported to modulate TRPM2
current response including Ca
2+ concentration, tempera-
ture, pH, phosphorylation, the epilepsy related protein
EFHC1, and CD38 [28,52,53]. Recently, TRPM2 currents
were shown to be inhibited by GSH in sensory neurons
[20] as well as in glial cells, where TRPM2 activation
following chemically induced GSH depletion contributes
to neuroinflammation [20,31]. Our own findings now
demonstrate that intrinsic alterations in endogenous
GSH content are associated with altered TRPM2 func-
tion in hippocampal pyramidal neurons. Collectively,
these studies suggest that GSH is a physiologically rele-
vant regulator of TRPM2 and that dynamic changes in
GSH content are likely to be associated with parallel
changes in TRPM2 function. Importantly, a reduction in
GSH has been associated with normal aging in vivo
[4-6,8,9]. Neurodegenerative disorders, including Parkin-
son’s disease and progressive supranuclear palsy, are
associated with enhanced depletion in intracellular GSH
compared to age-matched controls [10-12]. GSH deple-
tion is also observed following ischemia in animal mod-
els and in human subjects [13-16]. Diminished levels of
reduced GSH has also been linked to bipolar disorder,
major depressive disorder, and schizophrenia [54,55].
Importantly, upregulation of glutathione with NAC
treatment protects against ne u r o n a lc e l ld e a t hi nv i t r o
and in vivo [40,56-61].
The findings in this manuscript raise the intriguing
possibility that GSH depletion associated with aging,
ischemia, and several psychiatric and neurodegenerative
d i s o r d e r s ,m a yb ea s s o c i a t e dw i t he n h a n c e dT R P M 2
channel function. Future experiments will be required to
assess whether TRPM2 currents are also enhanced with
age in vivo, and/or in models of neurological disease
associated with GSH depletion. Furthermore, the contri-
bution of TRPM2 to neurodegeneration and dysfunction
associated with these conditions should be established.
Interestingly, depletion of GSH in Parkinson’si so n eo f
the earliest biochemical markers of impending neuronal
degeneration [12]. Moreover, TRPM2 is expressed and
functional in dopaminergic neurons of the substantia
nigra [62]. Accordingly, whether TRPM2 currents are
enhanced in models of Parkinson’s disease (or other neu-
rodegenerative disease in which GSH is depleted) and
whether knock-out of TRPM2 may attenuate neurode-
generation has yet to be investigated. Importantly, neuro-
degenerative diseases are well known to be associated
with pronounced neuroinflammatory response. Accord-
ingly, the demonstration that GSH depletion in glial cells
promotes neuroinflammation through a mechanism
involving TRPM2 [31], paired with our demonstration
that GSH depletion facilitates TRPM2 function in vulner-
able hippocampal pyramidal neurons, suggests that
TRPM2 activation contributes to neuronal demise in
neurodegenerative disease through multiple mechanisms.
By extension, TRPM2 may represent an important target
for the development of novel therapeutic agents of bene-
fit in the treatment of these debilitating neurological
diseases.
Conclusions
The results presented here indicate that GSH plays a
physiologically relevant role in the regulation of TRPM2
currents. The effects of GSH are thiol-independent and
cannot be recapitulated by reducing agents. Diminished
levels of reduced GSH may contribute to calcium dysre-
gulation through the loss of the TRPM2 tonic brake.
Therefore, this interaction may play an important role
in aging and neurological diseases associated with deple-
tion of GSH.
Methods
Reagents
Trypsin-EDTA, 5-fluorodeoxyuridine, uridine, CsOH,
Gluconic acid, MgCl2, CaCl2, BaCl2,E G T A ,K C l ,M g -
ATP, N-methyl-D-aspartate (NMDA), D-serine, Glucose,
Glutathione (GSH), L-Buthionine sulfoximine (L-BSO),
and N-acetyl-cysteine (NAC) were all purchased from
Sigma (Oakville, Ontario, Canada). HEPES and NaCl
were purchased from Bioshop (Burlington, Ontario,
Canada). Ophthalmic acid was obtained from Bachem
(Bubendorf, Switzerland).
Cell culture
Mouse hippocampal primary neuronal cultures were
prepared from CD-1 mice (Charles River, Wilmington,
MA, USA) at E17-19 as described previously with minor
adjustments [63]. Briefly, hippocampal tissue from
embryonic day 17-18 mice were dissected, enzymatically
and mechanically dissociation with 0.05% Trypsin-
EDTA, and plated at a density of < 1 × 10
6 cells ml
-1 on
collagen coated Nunc™ 35 mm culture dishes (Fisher,
Rochester, NY). After 3-5 days, each plate was treated
for 24 hours with 0.08 mM 5-fluorodeoxyuridine and
0.2 mM uridine. Cells were maintained for 4 weeks in
culture.
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Currents were recorded from mouse hippocampal pri-
mary neuronal cultures at 14-28 days in vitro. Whole-
cell voltage-clamp recordings were performed as
described previously, with minor adjustments [23].
Unless otherwise indicated, standard intracellular solu-
tion (ICS) contained (in mM): 150 cesium gluconate, 10
Hepes, and 2 MgCl2 and 1 ADPR. Standard extracellu-
lar solution (ECS) contained (in mM): 140 NaCl, 5.4
KCl, 25 Hepes, 33 glucose, 2 CaCl2, and 0.2 TTX.
TRPM2 currents were generated with either repeated
NMDAR activation or voltage ramps. NMDA currents
were elicited with 100 μMN M D Aa n d3μMd - s e r i n e
added to the standard ECS and applied for 5 or 10 sec-
onds every minute using a multibarrelled rapid perfu-
sion system (SF-77B; Warner Instruments, Hamden, CT,
USA). Voltage ramps (± 100 mV, 1/10 sec) were applied
in the presence of standard ECS supplemented with 1
mM MgCl2 and 1 mM BaCl2. After the TRPM2 current
stabilized, or after 10 minutes of recording, calcium free
solution was applied (total divalent concentration was
maintained by replacing CaCl2 with equimolar BaCl2).
Data were filtered at 2 kHz, digitized, and acquired
using pCLAMP and Axoscope software (Molecular
Devices, Sunnyvale, CA, USA).
Whole-cell recordings: TRPM2-HEK293
HEK 293 cells stably expressing an inducible flag-tagged
human TRPM2 (TRPM2-HEK293) were generously pro-
vided by Dr. A. M. Sharenberg (University of Washington,
Seattle, Washington). Cells were cultured at 37°C with 5%
CO2 in DMEM (Sigma) supplemented with 10% fetal
bovine serum and 1% penicillin/streptomycin (Invitrogen,
Burlington, ON, Canada). TRPM2 expression was induced
with doxycycline (1 μgm l
-1) 24 hours prior to experi-
ments. Intracellular solution (ICS) contained (in mM): 130
CsGluconate, 10 HEPES, 2 MgCl2, 1 CaCl2, 10 EGTA,
a n d4M g - A T P .I C Sw a sa d j u s t e dt oap Ho f7 . 3a n d
osmolarity between 295 and 300 mOsm. The final resis-
tance of ICS-filled electrodes was between 3 and 5 MΩ.
The standard extracellular solution (ECS) was composed
of (in mM): 140 NaCl, 5.4 KCl, 25 HEPES, 33 glucose,
1 MgCl2, 2 CaCl2, pH of 7.4 and osmolarity between 310
and 315 mOsm. Calcium-free ECS contained 2 mM BaCl2
in the place of CaCl2. Data were filtered at 2 kHz, digi-
t i z e d ,a n da c q u i r e du s i n gp C L A M Pa n dA x o s c o p es o f t -
ware (Molecular Devices). TRPM2-HEK293 cells were
held at -60 mV during whole-cell voltage-clamp record-
ings. Currents were evoked through the intracellular appli-
cation of ADPR at a concentration of 0.1 mM unless
otherwise indicated. Calcium containing ECS was applied
for 5 minutes or until a current of -1000pA developed, fol-
lowed by 2-3 minutes in calcium-free ECS. Calcium solu-
tion was then applied until the TRPM2 current began to
inactivate, and the amplitude of the TRPM2 current was
then determined after removal of extracellular Ca
2+.
Real-time quantitative polymerase chain reaction (QPCR)
Total RNA was extracted from primary mouse hippocam-
pal cultures at 15, 22, and 29 days in vitro (DIV) with Tri-
zol™ (Invitrogen, Burlington, Canada) according to the
manufacturer’s protocol. RNA concentration was quanti-
fied using the Nanodrop Spectrophotometer ND-1000
(Nanodrop technologies Inc., Wilmington, DE, USA). The
OD260/280 ratio for all samples was greater than 1.7. Fol-
lowing quantification, RNA was reverse transcribed using
Superscript™ II RT reagent according to the manufac-
turer’s guidelines, including the optional treatment with
40 units of RNaseOUT™ (Invitrogen). “No RT” controls
contained 1 μL H2O instead of Superscript™ II RT
reagent. The reaction was carried out in an Eppendorf
Mastercycler personal (Hamburg, Germany).
Primers were designed against the mouse TRPM2 cod-
ing strand (accession number NM_138301) and pur-
chased from Sigma. To test primer efficiency, a standard
curve was constructed from mouse hippocampal total
cDNA using 10x serial dilutions, ranging from 100 ng to
0.1 ng. Inclusion criteria for primers were an efficiency of
90-110%, and an R
2 value > 0.98.
To quantify TRPM2 mRNA, 100 ng of cDNA from each
sample was run in duplicate with iQ™ SYBR green Super-
mix (Biorad, Mississauga, Ontario) according to the manu-
facturer’s instructions. The BioRad MyiQTM iCycler was
used for real-time qPCR. Negative controls included the
No RT samples from reverse transcription and a no-tem-
plate control containing water instead of cDNA. Biorad
MyIQ™ 2.0 software was used for quantification of cycle
threshold. TRPM2 primers produced a 90 bp amplicon
using the sense sequence 5’TGATCCTGATGGCTGTG-
GAC3’ in combination with antisense sequence 5’AAGAG-
CAGAATGGCCCCA3’. The reaction was carried out at
95°C for 3 minutes, followed by 40 cycles of 95°C for 1 min-
ute and 55°C for 30 seconds. To control for potential varia-
tion in the number of neurons present in culture, cycle
thresholds for TRPM2 mRNA were normalized to neuron
specific enolase (ENO2) using the sense primer sequence
5’CTGCCTCTGAGTTTTACCGC3’ and the antisense pri-
mer sequence 5’TCCGGACAAAGTCCTGGTAG3’.
ENO2 was quantified with a thermal profile of 95°C for
3 minutes, followed by 40 cycles of 95°C for 1 minute and
62°C for 30 seconds. A a dissociation curve was run for
both primers using the following thermal profile: 95°C for
1 minute, 55°C for 1 minute, followed by a 2°C steps every
10 seconds from 70°C to 95°C.
Statistics
Data are expressed as mean ± SEM. Statistical analysis
was undertaken using GraphPad Prism
® (GraphPad
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Page 9 of 11Software, San Diego, CA). An unpaired two-tailed t-test,
ao n e - w a yA N O V Af o l l o w e db yaT u k e y ’sH S Dp o s t -
h o ct e s t ,o rat w o - w a yA N O V Af o l l o w e db yB o n f e r r o n i
post-hoc test was used to assess statistical significance.
Data was considered significant when p < 0.05.
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